Abstract
Nigrostriatal damage leads to a reduction in striatal nicotinic acetylcholine receptors (nAChRs) in rodents, monkeys, and patients with Parkinson's disease. The present studies were undertaken to investigate whether these nAChR declines are associated with alterations in striatal nAChR function and, if so, to identify the receptor subtypes involved. To induce nigrostriatal damage, mice were injected with the selective dopaminergic toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We measured [125I]3β-(4-iodophenyl)tropane-2β-carboxylic acid isopropyl ester (RTI-121, dopamine transporter),125I-α-conotoxin MII (putative α6-containing sites in the central nervous system), 125I-epibatidine (multiple sites), 5-[125I]iodo-3-[2(S)-azetidinylmethoxy]pyridine-2HCl ([125I]A85380; β2-containing sites), and125I-α-bungarotoxin (α7-containing sites) binding in brains from control and MPTP-treated mice, as well as nAChR function by [3H]dopamine release, [3H]GABA release, and [86Rb+] efflux. After MPTP treatment, declines were observed in striatal dopamine transporter levels, both binding and functional measures of striatal α-conotoxin MII-sensitive nAChRs, and selected measures of striatal α-conotoxin MII-resistant nAChRs. In contrast, 125I-α-bungarotoxin binding sites were not altered after nigrostriatal damage. The changes in striatal nAChRs were selective, with no declines in cortex, thalamus, or septum. Those striatal binding and functional measures of nAChRs that decreased with MPTP treatment correlated with dopamine transporter declines, an observation suggesting that the binding and functional changes in nAChRs are limited to dopaminergic terminals. The present results are the first to demonstrate differential alterations in nAChR subtype function after nigrostriatal damage, with a close correspondence between changes in receptor binding sites and function. These data suggest that the declines in nAChR sites observed in Parkinson's disease brains may be of functional significance.
Footnotes
-
This work was supported by the California Tobacco Related Disease Research Program 11RT-0216 (to M.Q.), National Institute of Neurological Disorders and Stroke grant NS42091 (to M.Q.), National Institute on Drug Abuse grants DA12242 (to M.J.M.), DA00197 (to A.C.C.), and DA03194 (to A.C.C.), National Institute of Mental Health grant MH53631 (to J.M.M.), National Institute of General Medical Sciences grant GM48677 (to J.M.M.), and Colorado Tobacco Research Program CTRP 2R-033 (to A.C.C.).
- Abbreviations:
- nAChR
- nicotinic acetylcholine receptor
- [125I]A85380
- 5-[125I]iodo-3-[2(S)-azetidinylmethoxy]pyridine-2HCl
- MPTP
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- RTI-121
- 3β-(4-iodophenyl)tropane-2β-carboxylic acid isopropyl ester
- *
- nicotinic receptors containing the indicated α and/or β subunit and possibly additional undefined subunits
- dopa
- 3,4-dihydroxyphenylalanine
- BSA
- bovine serum albumin
- Received January 8, 2003.
- Accepted February 12, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|